Gedeon Richter: Cariprazine shows effectiveness in the treatment of mental health disorders with combined substance use disorder

In addition, Richter and Recordati organized a scientific symposium titled "Partial activity, full impact: innovations in schizophrenia treatment", where experts discussed the potential of dopamine receptor partial agonists and the importance of understanding the mechanism of action to differentiate and personalize therapies. In addition, Richter and Recordati organized a scientific symposium titled " Partial activity, full impact: innovations in schizophrenia treatment ", where experts...

In addition, Richter and Recordati organized a scientific symposium titled "Partial activity, full impact: innovations in schizophrenia treatment", where experts discussed the potential of dopamine receptor partial agonists and the importance of understanding the mechanism of action to differentiate and personalize therapies.

On the 4^th of April, during a Scientific Event involving around 100 doctors, the importance of utilizing measurement-based care in everyday psychiatric practice was highlighted: Professor Christoph U. Correll and an expert from Gedeon Richter presented a novel transdiagnostic scalefor quantifying-visualizing symptom severity in patients with different psychiatric conditions.

Cariprazine is available in 67 countries globally, and the number of total patients treated from launch in Europe and US is around 1.700.000 (different indications).

About Richter

About Recordati

About Cariprazine

Media-contact: Zsuzsa Beke, Head of PR, [email protected]

View original content:https://www.prnewswire.co.uk/news-releases/gedeon-richter-cariprazine-shows-effectiveness-in-the-treatment-of-mental-health-disorders-with-combined-substance-use-disorder-302423265.html